Results 61 to 70 of about 1,494 (190)

Irradiation‐Induced CD62L Shedding in Human Plasmacytoid Dendritic Cells Depends on ADAM17 and p38 MAPK

Immunology, EarlyView.
Human plasmacytoid dendritic cell‐based vaccines efficiently migrate from blood to lymph nodes and prime naive T cells in humanised mice. Irradiation‐induced CD62L shedding, mediated by p38 MAP kinase and ADAM17, is involved in the regulation of PDC migration to secondary lymphoid organs in this model.
Estelle Leplus, Jamila Kacher, Dalil Hannani, Guillaume Vayssiere, Jean‐Paul Molens, Karine Laulanier, Dan Georgess, Véronique Josserand, Philippe Saas, Séverine Planel, Laurence Chaperot, Joel Plumas   +11 more
wiley   +1 more source

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm

Therapeutic Advances in Hematology, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of dendritic cells and involves most frequently the skin, bone marrow and lymph nodes. Diagnosis depends upon identification of
Minas P. Economides, Marina Konopleva, Naveen Pemmaraju   +2 more
doaj   +1 more source

Unusual presentation of blastic plasmacytoid dendritic cell neoplasm: Pitfalls in other hematolymphoid neoplasms

Human Pathology: Case Reports, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+/CD56+ hematological malignancy with aggressive clinical course and poor prognosis.
Alexis Trecourt, Brigitte Balme, Marie-Hélène Lorton, Juliette Fontaine, Pauline Desormeaux, Cédric Rossi, Jean-Noël Bastie, Ingrid Lafon, Géraldine Jeudy, Sophie Dalac, Sarah Huet, Pierre Sujobert, Claire Mauduit, Alexandra Traverse-Glehen   +13 more
doaj   +1 more source

Nowotwór z blastycznych plazmocytoidnych komórek dendrytycznych (BPDCN) — wyzwanie diagnostyczne i terapeutyczne

, 2021
Nowotwór z blastycznych plazmocytoidnych komórek dendrytycznych (BPDCN) jest rzadkim i agresywnym nowotworem hematologicznym. Choroba zwykle zajmuje skórę, szpik kostny, krew obwodową oraz — rzadziej — węzły chłonne.
Kluge, Przemysław; Zakład Diagnostyki Laboratoryjnej, Mazowiecki Szpital Onkologiczny w Wieliszewie, Jesionek-Kupnicka, Dorota; Zakład Patologii, Katedra Onkologii, Uniwersytet Medyczny w Łodzi, Drążek, Lucyna; Zakład Diagnostyki Laboratoryjnej, Mazowiecki Szpital Onkologiczny w Wieliszewie, Wajs, Jarosław; Oddział Hematologii, Mazowiecki Szpital Onk ologiczny w Wieliszewie, Lewandowska, Małgorzata; Zakład Patomorfologii i Cytopatologii Klinicznej, Uniwersytet Medyczny w Łodzi   +4 more
core  

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data

, 2020
International audienceBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes.
Beziat, Guillaume, Ysebaert, Loïc
core   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo, Miriam A. Bornhorst, Angela J. Waanders, Sara Zarnegar‐Lumley, Ashwin Lakshman Koppayi, Lucy A. Godley   +5 more
wiley   +1 more source

Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment

Frontiers in Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of <2 years. Especially, most BPDCN patients present with extensive and non-specific skin lesions,
Xiaoning Wang, Xiaoning Wang, Jiashuo Guo, Jiashuo Guo, Yan Liu, Na Zheng, Shaohan Xu, Shaohan Xu, Lianhui Wu, Ruirui Yuan, Liying Xue, Jie Li   +11 more
doaj   +1 more source

Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia

Human Vaccines & Immunotherapeutics, 2020
The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss, Mary Clark, Joo Y Song, Vinod Pullarkat   +3 more
doaj   +1 more source

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

Cytometry Part B: Clinical Cytometry, Volume 110, Issue 5, Page 326-334, September 2026.
Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean, Tracy I. George, David P. Ng   +2 more
wiley   +1 more source